559 related articles for article (PubMed ID: 22464800)
1. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
Harris WJ; Huang X; Lynch JT; Spencer GJ; Hitchin JR; Li Y; Ciceri F; Blaser JG; Greystoke BF; Jordan AM; Miller CJ; Ogilvie DJ; Somervaille TC
Cancer Cell; 2012 Apr; 21(4):473-87. PubMed ID: 22464800
[TBL] [Abstract][Full Text] [Related]
2. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
3. Enhancers of Polycomb EPC1 and EPC2 sustain the oncogenic potential of MLL leukemia stem cells.
Huang X; Spencer GJ; Lynch JT; Ciceri F; Somerville TD; Somervaille TC
Leukemia; 2014 May; 28(5):1081-91. PubMed ID: 24166297
[TBL] [Abstract][Full Text] [Related]
4. Learning from mouse models of MLL fusion gene-driven acute leukemia.
Schwaller J
Biochim Biophys Acta Gene Regul Mech; 2020 Aug; 1863(8):194550. PubMed ID: 32320749
[TBL] [Abstract][Full Text] [Related]
5. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
6. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
[TBL] [Abstract][Full Text] [Related]
7. Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?
Somervaille TC; Cleary ML
Int J Hematol; 2010 Jun; 91(5):735-41. PubMed ID: 20454944
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia.
Wei J; Wunderlich M; Fox C; Alvarez S; Cigudosa JC; Wilhelm JS; Zheng Y; Cancelas JA; Gu Y; Jansen M; Dimartino JF; Mulloy JC
Cancer Cell; 2008 Jun; 13(6):483-95. PubMed ID: 18538732
[TBL] [Abstract][Full Text] [Related]
9. shRNA screening identifies JMJD1C as being required for leukemia maintenance.
Sroczynska P; Cruickshank VA; Bukowski JP; Miyagi S; Bagger FO; Walfridsson J; Schuster MB; Porse B; Helin K
Blood; 2014 Mar; 123(12):1870-82. PubMed ID: 24501218
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
[TBL] [Abstract][Full Text] [Related]
11. Bioflavonoids promote stable translocations between MLL-AF9 breakpoint cluster regions independent of normal chromosomal context: Model system to screen environmental risks.
Bariar B; Vestal CG; Deem B; Goodenow D; Ughetta M; Engledove RW; Sahyouni M; Richardson C
Environ Mol Mutagen; 2019 Mar; 60(2):154-167. PubMed ID: 30387535
[TBL] [Abstract][Full Text] [Related]
12. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia.
Chu Y; Chen Y; Li M; Shi D; Wang B; Lian Y; Cheng X; Wang X; Xu M; Cheng T; Shi J; Yuan W
Cancer Sci; 2019 Jul; 110(7):2200-2210. PubMed ID: 31050834
[TBL] [Abstract][Full Text] [Related]
13. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
14. An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model.
Bergerson RJ; Collier LS; Sarver AL; Been RA; Lugthart S; Diers MD; Zuber J; Rappaport AR; Nixon MJ; Silverstein KA; Fan D; Lamblin AF; Wolff L; Kersey JH; Delwel R; Lowe SW; O'Sullivan MG; Kogan SC; Adams DJ; Largaespada DA
Blood; 2012 May; 119(19):4512-23. PubMed ID: 22427200
[TBL] [Abstract][Full Text] [Related]
15. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
17. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
Osaki H; Walf-Vorderwülbecke V; Mangolini M; Zhao L; Horton SJ; Morrone G; Schuringa JJ; de Boer J; Williams O
Leukemia; 2013 Jul; 27(7):1461-8. PubMed ID: 23403462
[TBL] [Abstract][Full Text] [Related]
18. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
Chiarella E; Aloisio A; Scicchitano S; Todoerti K; Cosentino EG; Lico D; Neri A; Amodio N; Bond HM; Mesuraca M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639154
[TBL] [Abstract][Full Text] [Related]
19. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells.
Chen W; Kumar AR; Hudson WA; Li Q; Wu B; Staggs RA; Lund EA; Sam TN; Kersey JH
Cancer Cell; 2008 May; 13(5):432-40. PubMed ID: 18455126
[TBL] [Abstract][Full Text] [Related]
20. Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7 and -A10 genes and induces apoptosis in a human leukemia cell line, THP-1.
Kawagoe H; Kawagoe R; Sano K
Leukemia; 2001 Nov; 15(11):1743-9. PubMed ID: 11681416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
